...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochemical Pharmacology >Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
【24h】

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

机译：修复现有药物治疗Covid-19 / SARS-COV-2感染：描述药物作用机制的综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The outbreak of a novel coronavirus (SARS-CoV-2) has caused a major public health concern across the globe. SARS-CoV-2 is the seventh coronavirus that is known to cause human disease. As of September 2020, SARS-CoV-2 has been reported in 213 countries and more than 31 million cases have been confirmed, with an estimated mortality rate of similar to 3%. Unfortunately, a drug or vaccine is yet to be discovered to treat COVID-19. Thus, repurposing of existing cancer drugs will be a novel approach in treating COVID-19 patients. These drugs target viral replication cycle, viral entry and translocation to the nucleus. Some can enhance innate antiviral immune response as well. Hence this review focuses on comprehensive list of 22 drugs that work against COVID-19 infection. These drugs include fingolimod, colchicine, N4-hydroxycytidine, remdesivir, methylprednisone, oseltamivir, icatibant, perphanizine, viracept, emetine, homoharringtonine, aloxistatin, ribavirin, valrubicin, famotidine, almitrine, amprenavir, hesperidin, biorobin, cromolyn sodium, and antibodiestocilzumab and sarilumab. Also, we provide a list of 31 drugs that are predicted to function against SARS-CoV-2 infection. In summary, we provide succinct overview of various therapeutic modalities. Among these 53 drugs, based on various clinical trials and literature, remdesivir, nelfinavir, methylpredinosolone, colchicine, famotidine and emetine may be used for COVID-19.
机译：新型冠状病毒（SARS-COV-2）的爆发导致全球主要的公共卫生问题。 SARS-COV-2是已知引起人类疾病的七冠状病毒。截至2020年9月，SARS-COV-2已在213个国家报告，已确认超过3100万个案件，估计死亡率与3％相似。不幸的是，尚不发现药物或疫苗来治疗Covid-19。因此，治疗现有癌症药物将是治疗Covid-19患者的新方法。这些药物靶向病毒复制循环，病毒进入和核心易位。有些人也可以增强天生的抗病毒免疫反应。因此，本综述重点介绍了22种符合Covid-19感染的药物清单。这些药物包括Fingolimod，Colchicine，N4-羟基胞苷，甲羟哌啶，甲磺酰胺，亲属，亲属，viracep，emetinine，Homoharingtonine，Aloxistatin，Ribavirin，Valrubicin，Famotidine，Almitrine，Amprenavir，Hesperidin，Biorobin，Cromolynab和anticitiestocilzumab和Sarilumab 。此外，我们提供了31种药物的列表，预计将针对SARS-COV-2感染功能。总之，我们提供了各种治疗方式的简洁概述。在这53种药物中，基于各种临床试验和文献，雷代肽，奈贝韦吡啶醇，甲基预吡啶醇，血清序列，氟喹和庚酮可用于Covid-19。

著录项

  • 来源
    《Biochemical Pharmacology》 |2021年第1期|共14页
  • 作者

    Yousefi Hassan; Mashouri Ladan; Okpechi Samuel C.; Alahari Nikhilesh; Alahari Suresh K.;

  • 作者单位

    Louisiana State Univ Hlth Sci Ctr Sch Med Dept Biochem &

    Mol Biol New Orleans LA USA;

    Univ Arkansas Dept Med Sci Little Rock AR USA;

    Louisiana State Univ Hlth Sci Ctr Sch Med Dept Biochem &

    Mol Biol New Orleans LA USA;

    Louisiana State Univ Dept Biol Engn Baton Rouge LA USA;

    Louisiana State Univ Hlth Sci Ctr Sch Med Dept Biochem &

    Mol Biol New Orleans LA USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号